

5th April 2016

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – IQN Acquires Interest in Novel and First in Class Biologic Compound Originated at McGill University

iQn Ltd (NSX:IQN) is pleased to announce that it has acquired a majority interest in a consortium that owns and is commercialising a novel and first in class biologic compound, accompanying biomarker and genetic stem cell development program. The research program and the resulting intellectual property originated from McGill University in Canada. The current clinical development strategy has a global focus, however it is anticipated that Australia will play a major role in the clinical development of this novel antineoplastic compound.

Currently the compound will be exiting the preclinical phase and in the next few months we intend to file with the US regulatory agency an Investigative New Drug Application that will enable us to commence Phase I clinical trials.

This novel biologic compound and its Biomarker are being developed for multiple oncology indications. Primarily the development plan is focused on breast cancer, melanoma and prostate cancer.

The Chairman of iQnovate, Dr George Syrmalis stated “This is a compound that has been developed by a prestigious research institute over a number years and we are extremely happy to be leading the way in its commercialisation. At a time when everybody is talking about personalised medicine, we are taking the lead in making it happen. This is a tremendous opportunity, for the patients that will

gain early access to this compound, our investors and our country which will be a co-host to the development of this compound”.

Further information will be released to the market in due course as the program progresses.

For and on behalf of the Board.



Kelvin Boateng
Company Secretary
iQnovate Ltd

For further information, please contact our Corporate Advisors below:

Investors

iQ3Corp Investor Relations Team
Email: investor.relations@iq3corp.com
Phone: +61 2 8239 5400

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

Safe Harbor Statement

Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Ltd

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.